四种结构多样化的SUR2-含有KATP通道的抑制剂的表征
Kangjun Li1,2, Vaishali Satpute Janve2, Jerod Denton1,2,3
1Department of Pharmacology, Vanderbilt University, Nashville, TN.
Channels (Austin, Tex.)
|September 20, 2024
概括
研究人员发现了新的化合物,可以选择性地抑制血管光滑肌肉ATP敏感 (KATP) 通道. 这些新型抑制剂为开发针对心血管疾病的药物提供了潜力.
科学领域:
- 心血管药理学心血管药理学
- 离子通道生物学 离子通道生物学
- 药物发现 药物发现 药物发现
背景情况:
- 血管光滑肌肉ATP敏感 (KATP) 通道对于调节血管度至关重要,是心血管疾病的重要药物标.
- 开发选择性KATP通道抑制剂,特别是针对血管亚型 (Kir6.1/SUR2B) 而不是胰腺/大脑亚型 (Kir6.2/SUR1),一直是一个长期存在的挑战.
- 之前的研究发现,VU0542270是第一个强效和选择性的Kir6.1/SUR2B抑制剂.
研究的目的:
- 识别和描述新型,结构上不同的血管Kir6.1/SUR2B通道的抑制剂.
- 评估这些新化合物的选择性与其他KATP通道亚型相比,特别是Kir6.2/SUR1.1.
- 阐明这些新型抑制剂的作用机制.
主要方法:
- 对各种化学库进行高通量选,以发现Kir6.1/SUR2B抑制剂.
- 药理学表征包括IC50测定Kir6.1/SUR2B和Kir6.2/SUR1通道的抑制.
- 对异质表达的KATP通道子单元组合 (Kir6.1,Kir6.2,SUR1,SUR2A,SUR2B) 的功能分析.
主要成果:
- 确定了四种新的Kir6.1/SUR2B抑制剂 (VU0212387,VU0543336,VU0605768,VU0544086),其IC50值在100nM~1μM之间.
- 这些化合物表现出选择性,在测试度下没有显著抑制Kir6.2/SUR1通道.
- 功能性研究表明,所有四种抑制剂都准SUR2亚单元以诱导通道抑制;VU0543336和VU0212387在较高剂量时显示出对Kir6.2/SUR1具有矛盾的刺激作用.
结论:
- 这项研究扩大了选择性Kir6.1/SUR2B通道抑制剂的范围.
- 这些已识别的化合物代表了对KATP道药理学的进一步研究有价值的化学工具.
- 这些新型抑制剂为开发针对心血管疾病的向治疗提供了基础.
相关概念视频
Enzymes
81.1K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
81.1K
Voltage-gated Ion Channels
8.0K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
8.0K
Secondary Active Transport
6.9K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.9K
Ligand-gated Ion Channels
12.3K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
12.3K
Enzyme Inhibition
78.1K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.1K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
542
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
542


